by Admin CP | 25 Mar 2021
Precision on the press release dated March 19, 2021 March 19, 2021 Paris, France, March 19, 2021 – 6.00 pm CET – Advicenne (Euronext: ADVIC) (the “Company”), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments...
by Admin CP | 19 Mar 2021
Advicenne expects imminent marketing authorization for ADV7103 (Sibnayal™) for dRTA in Europe March 19, 2021 Paris, France, March 19, 2021 – 6.00 pm CET – Advicenne (Euronext: ADVIC) (the “Company”), a specialty pharmaceutical company dedicated to developing...
by Admin CP | 18 Feb 2021
Advicenne Provides an Update as its Operations Evolve February 18, 2021 Paris, France, February 18, 2021 (6:00 pm CET) – Advicenne (Euronext: ADVIC) provides an update on the overall progress of the Company. Back to all press releases Open...
by Admin_Advicenne | 7 Jan 2021
Advicenne Announces the Appointment of Peter Meeus as Chief Executive Officer January 10, 2021 Paris, France, January 7, 2021 – 7.00 am CET – Advicenne (Euronext: ADVIC) today announced the appointment of Peter Meeus as Chief Executive Officer of Advicenne,...
by Admin_Advicenne | 10 Dec 2020
Advicenne receives positive CHMP opinion recommending approval of ADV7103 (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA) December 10, 2020 Paris, France, December 10, 2020 (6.00 pm CET) – Advicenne (Euronext: ADVIC) today announces the...
